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Abstract: This study investigates GT-1 (also known as LCB10-0200), a novel-siderophore
cephalosporin, inhibited multidrug-resistant (MDR) Gram-negative pathogen, via a Trojan horse
strategy exploiting iron-uptake systems. We investigated GT-1 activity and the role of siderophore
uptake systems, and the combination of GT-1 and a non-β-lactam β-lactamase inhibitor (BLI) of
diazabicyclooctane, GT-055, (also referred to as LCB18-055) against molecularly characterised resistant
Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. isolates. GT-1 and GT-1/GT-055 were tested
in vitro against comparators among three different characterised panel strain sets. Bacterial resistome
and siderophore uptake systems were characterised to elucidate the genetic basis for GT-1 minimum
inhibitory concentrations (MICs). GT-1 exhibited in vitro activity (≤2 µg/mL MICs) against many
MDR isolates, including extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing
E. coli and K. pneumoniae and oxacillinase (OXA)-producing Acinetobacter spp. GT-1 also inhibited
strains with mutated siderophore transporters and porins. Although BLI GT-055 exhibited intrinsic
activity (MIC 2–8 µg/mL) against most E. coli and K. pneumoniae isolates, GT-055 enhanced the activity
of GT-1 against many GT-1–resistant strains. Compared with CAZ-AVI, GT-1/GT-055 exhibited lower
MICs against E. coli and K. pneumoniae isolates. GT-1 demonstrated potent in vitro activity against
clinical panel strains of E. coli, K. pneumoniae and Acinetobacter spp. GT-055 enhanced the in vitro
activity of GT-1 against many GT-1–resistant strains.
Keywords: GT-1; GT-055; siderophore-cephalosporin; β-lactamase inhibitor
1. Introduction
The World Health Organisation has prioritised third-generation cephalosporin and
carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii as critical pathogens for research
and development of new antibiotic drugs [1]. More importantly, the emergence of strains co-harbouring
carbapnemases, such as blaKPC-2 or blaNDM-9, and colistin resistance gene, such as mcr-1, have made
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treatment more challenging [2,3]. This has highlighted the importance of developing new antibiotics
to address the problem of antibiotic resistance. However, in contrast to the rapid and continuous
escalation in the emergence of multidrug-resistant (MDR) Gram-negative bacteria and the diminishing
efficacy of the current antibiotic arsenal, there has been a lag in investment in new research and
drug development [1]. A bottleneck in current approaches for designing novel antibiotics is the
limited number of drug targets, such as components of nucleic acid synthesis and cell wall assembly,
or bacterial ribosomes [4].
Since the first antibiotics were discovered, Gram-negative bacteria have developed various
resistance mechanisms, such as hydrolysis or modification of antibiotics, reducing antibiotic uptake via
loss of porins, reducing the affinity of antibiotic-target binding and increasing the expression of efflux
pumps [5,6]. Moreover, the outer membrane barrier is a crucial resistance determinant in Gram-negative
bacteria, as reduced permeability of the cell wall potentiates other antibiotic resistance mechanisms.
The novel siderophore-cephalosporin GT-1 (previously known as LCB10-0200) is in development
by LegoChem Biosciences (Daejeon, Korea) and Geom Therapeutics (San Francisco, CA, USA).
This compound is a conjugate of a novel siderophore-dihydroxypyridone and a modified
aminothiazolylglycyl cephalosporin and exploits bacterial iron-uptake systems to enhance entry into
Gram-negative pathogens using a “Trojan-horse” strategy [7] (Figure 1a). First, this approach opens a
more efficient route for the antibiotic to enter the bacterial periplasm via siderophore-uptake systems.
Second, the conjugated structure resists the hydrolytic activity of many current extended-spectrum
β-lactamases and carbapenemases. As a result, GT-1 exhibits activity against many MDR pathogens.
One well-described strategy to enhance the activity of β-lactam antimicrobials in the presence of
β-lactamases is to combine them with β-lactam inhibitors (BLIs) [8]. In the last 5 years, new generations
of BLIs have been approved for clinical use, including vaborbactam (cyclic boronic acid BLI) and
avibactam (diazabicyclooctane BLI) [9,10]. GT-055 (also referred to as LCB18-055), in development by
LegoChem Biosciences and Geom Therapeutics, is a novel non-β-lactam BLI of the diazabicyclooctane
class [11] (Figure 1b).
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Figure 1. Structures of GT-1 and GT-055. (a) Chemical structure of GT-1 (previously known as
LCB10-0200). (b) Chemical structure of GT-055 (previously known as LCB18-055).
In a previous study, Oh et al. characterised the in vitro activity of GT-1, focusing primarily
on Pseudomonas aeruginosa [7]. Only 17 P. aeruginosa strains with identified β-lactamases (OXA-2,
OXA-10, OXA-17, VIM and IMP) were investigated. Even though the in vitro activity of GT-1 was
also determi ed in other species, such as Escherichia coli, Klebsiella pneumoniae and A. baumannii, the
resisto e profile of the tested strains has not been described. In this study, the in vitro activity of T-1
and other antibiotics was investigate against anels of characterise isolates of . coli, . pneumoniae
and Acinetobacter spp., which exhibit a variety of β-lactam resistance mechanisms. Additionally, this is
the first study to examine the synergistic combination of GT-1 and GT-055 and co pare its potency to
other combinations, such as azithromycin/avibactam and ceftazidime/avibactam. Until now, there has
been no systematic investigation of the correlation between GT-1 potency and the different iron uptake
systems of E. coli, . p e oniae a ci etobacter spp. clinical isolates. Moreover, there has been no
report describing other mechanisms that can contribute to resistance to GT-1, such as GT-1 hydrolysis
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or porin loss. Thus, this study was undertaken to elucidate the genomic characteristics of the panel
strains and associated GT-1 minimal inhibitory concentrations (MICs).
2. Results
2.1. In Vitro Activity of GT-1 and GT-1/GT-055 against E. coli Panel Strains
GT-1 activity was tested against isolates producing a wide range of β-lactamases. The strains were
isolated from different specimen types, including stool (9 isolates), blood (1 isolate), pus (1 isolate),
respiratory tract (1 isolate) and peritoneal fluid (1 isolate). The β-lactamase producers present in these
diverse specimens included strains producing non-extended-spectrum β-lactamase (ESBLs) (TEM-1B,
TEM-1C, SHV-11, OXA-1, OXA-10), ESBLs (CTX-M-14, CTX-M-15, CTX-M-27, CTX-M-55, CTX-M-65),
AmpC (ACT-2, CMY-2) and carbapenemases (KPC-2, OXA-48) (Table 1). The strains were classified
into six categories: non-ESBL-producing (YMC2016/07/N348), ESBL-producing (YMC2016/06/N138,
YMC2017/02/N55), ESBL- and AmpC β-lactamase-producing (YMC2017/02/N19), AmpC β-lactamase- and
carbapenemase-producing (YMC2017/07/B11634), ESBL- and carbapenemase-producing (YMC2016/02/N176,
YMC2016/06/N255, YMC2017/04/N120, YMC2017/06/P238) and carbapenemase-producing
(YMC2016/01/N95, YMC2016/01/C905, YMC2016/04/R3267, YMC2016/10/N189) (Table 1).
The GT-1 MICs ranged from ≤0.12 to 1 µg/mL against E. coli MDR isolates producing KPC-
or OXA-carbapenemases, ESBLs CTX-M-14 or CTX-M-55 and CMY-2 AmpC β-lactamase. These
MICs were lower in comparison to those for carbapenem, which ranged from 0.25 to 16 µg/mL, or in
comparison to MICs for ceftazidime, which ranged from 1 to 64 µg/mL. Against CTX-M-negative but
carbapenemase-producing E. coli, GT-1 MICs were ≤0.25 µg/mL, whereas carbapenem MICs ranged
from 0.5 to 16 µg/mL. ESBL-producing E. coli strains (CTX-M-15, CTX-M-27, CTX-M-65) and strains
overexpressing ACT-2 exhibited GT-1 MICs of 4–32 µg/mL.
In combination with the β-lactamase inhibitor GT-055 (at 4 µg/mL), GT-1/GT-055 MICs for all
strains decreased to ≤0.12 µg/mL, similar to or lower than the MICs for the combination of CAZ-AVI
(Table 1). GT-055 alone exhibited activity against the E. coli isolates with MICs ranging from 2 to
8 µg/mL.
The siderophore uptake system and ompC and ompF integrity were investigated to evaluate the
contribution of the siderophore transporters and porin loss to the MIC of GT-1 (Table 2). There were no
deletions or early terminations in the tonB, exbB, exbD, fiu, or fepA genes in any of the isolates. The GT-1
MIC was ≤0.5 µg/mL with the triple deletion of fecA, fhuA and iroN in strain YMC2016/06/N138
or the deletion of fecA, iutA, fyuA and iroN in strains YMC2017/07/B11634, YMC2016/01/N95,
YMC2016/10/N189, as well as the deletion of iutA, fhuA and iroN in strain YMC2016/06/N255.
Furthermore, the deletion of both ompC and ompF in strain YMC2016/06/N138 and deletion of
ompF in strain YMC2016/10/N189 did not appear to be associated with increases in GT-1 MIC. Although
strain YMC2016/02/N176 exhibited a high GT-1 MIC of 8 µg/mL, there was one observed deletion of
fyuA without porin loss. In this case, the β-lactamases present were likely responsible for the high
MIC, as the combination with GT-055 reduced the MIC to ≤0.12 µg/mL.
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Table 1. Antibiotic susceptibility and resistome of the Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. panel strains.
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Table 2. Porins and siderophore uptake systems of E. coli, K. pneumoniae and Acinetobacter spp.
panel strains.
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carbapenem MICs. Among five isolates expressing the DHA-1 β-lactamase, four isolates exhibited high
GT-1 MICs (4–64 µg/mL). Although strain YMC2016/04/N62 was resistant to colistin (MIC = 32 µg/mL),
it exhibited a GT-1 MIC of 0.5 µg/mL. To directly assess the activity of GT-1 in the presence of DHA-1
β-lactamase, blaDHA-1 was cloned into ZpUC19 and transformed into E. coli DH5α, which resulted in a
16-fold increase in the GT-1 MIC compared to the control carrying the empty ZpUC19 vector (Table 3).
However, in combination with the β-lactamase inhibitor GT-055, the GT-1/GT-055 MICs decreased
to ≤0.12 µg/mL, except for strains YMC2010/10/P347 and YMC2012/08/C631. In YMC2010/10/P347,
the GT-1 MIC decreased 4-fold to 16 µg/mL when combined with GT-055, which was similar to the MIC
for GT-055 alone. No change in GT-1 MIC (0.5 µg/mL) was observed against strain YMC2012/08/C631
(IMP-1) in combination with GT-055.
Table 3. Minimum inhibitory concentrations (MICs) of transformed E. coli DH5α strains.
Strain GT-1 MIC (µg/mL) Fold Change
DH5α+ ZpUC19::blaDHA-1 0.5 ↑ 16-fold
DH5α+ ZpUC19::blaPER-1 32 ↑ 1024-fold
DH5α+ ZpUC19 0.03125 −
↑: the arrow indicated the increase in fold change.
The siderophore uptake systems and integrity of ompK35 and ompK36 were also investigated to
elucidate the role of the siderophore transporters and porin loss on GT-1 MICs against K. pneumoniae
(Table 2). No deletion or early termination of tonB or exbD was observed, but iroN was absent in all of
the isolates. The deletion of exbB was observed in strain YMC2011/8/B10311, but the GT-1 MIC was
low at 0.5 µg/mL. The GT-1 MIC was ≤1 µg/mL in strain YMC2011/07/B7207, in which fecA, fiu and
fyuA were deleted; in strain YMC2013/7/B3993 in the absence of fepD, fiu, cirA and fyuA, in strain
YMC2011/7/B774 with the deletion of fecA, fiu, fhuA and fyuA, and in strain YMC2012/8/C631 with
the deletion of fecA, fiu, cirA, fhuA and fyuA. Additionally, the single deletion of ompK35 in strain
YMC2013/7/B3993 and double deletion of ompK35 and ompK36 in strain YMC2010/10/R2142 did not
result in high GT-1 MICs. This suggested that mutations in the siderophore transporter genes fecA,
fiu, cirA, fhuA, or fyuA and the porin genes ompK35 or ompK36 do not markedly affect GT-1 MICs.
Early termination of fiu in strain YMC2011/7/B36 and deletion of fecA in strain YMC2011/11/B7578
were associated with GT-1 MICs of 16 and 64 µg/mL, respectively. However, similar mutations were
also observed in strains exhibiting low GT-1 MICs, so the importance, if any, of these mutations in
determining GT-1 MICs in strains YMC2011/7/B36 and YMC2011/11/B7578 remains unclear. Although
there was only one deletion of iroN in the siderophore uptake system in strain YMC2010/10/P347, this
strain exhibited a high GT-1 MIC of 64 µg/mL. The low MIC for the combination of GT-1/GT-055 with
this isolate (relative to GT-1 alone or GT-055 alone) was consistent with the high GT-1 MICs reflecting
the activity of β-lactamases inhibited by GT-055.
2.3. In Vitro Activity of GT-1 and GT-1/GT-055 against Acinetobacter spp. Panel Strains
The antimicrobial activity of GT-1 and GT-055 was examined against Acinetobacter spp.
isolates exhibiting various β-lactam resistance mechanisms, including one narrow-spectrum
oxacillinase–producing strain, three ESBL- and AmpC-co-producing strains, two AmpC- and
carbapenemase-co-producing strains and five ESBL-, AmpC- and carbapenemase-co-producing strains.
The broad range of β-lactamase producers represented among the panel strains included non-ESBL
(CARB-8, TEM-1D), ESBL (PER-1, OXA-66), AmpC (ADC-22, ADC-25, ADC-30, ADC-31, ADC-77),
and carbapenemase (OXA-23, OXA-82, OXA-120, OXA-213, OXA-421, OXA-499, OXA-506, SIM-1)
producers (Table 1). The samples were isolated from different sources, including stool (6 isolates),
blood (2 isolates), peritoneal fluid (2 isolates), and catheter tip (1 isolate).
GT-1 MICs ranged from 0.5 to 2 µg/mL among isolates producing OXA-ESBL (OXA-66),
OXA-carbapenemases (OXA-23, OXA-82, OXA-120, OXA-213, OXA-421, OXA-499), and ADC-type
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(ADC-25, ADC-30, ADC-77) AmpC β-lactamases. A reduction of >64- to 256-fold in GT-1 MICs was
observed when compared to ceftazidime (MICs 4 to >256 µg/mL), and a 16- to 64-fold reduction was
observed when compared to carbapenem (MICs 0.5 to 32 µg/mL). Nonetheless, strains producing PER-1
exhibited high GT-1 MICs, ranging from 16 to 256 µg/mL, and E. coli DH5α encoding ZpUC19::blaPER-1
exhibited a 1024-fold increase in GT-1 MIC in comparison with E. coli DH5α harbouring the empty
vector (Table 3). The increase in GT-1 MIC supports the hypothesis that GT-1 is susceptible to PER-1
β-lactamase.
GT-1, in combination with GT-055, decreased the MICs for several ESBL-AmpC- and ESBL-AmpC
carbapenemase-producing isolates. In particular, the GT-1 MIC decreased by 32-fold in strain
YMC2003/01/R306, which produces PER-1 and ADC-25. In addition, a 32-fold reduction in GT-1 MIC
from 256 to 8 µg/mL was observed in strain YMC2003/05/C86, which produces PER-1, ADC-31 and
OXA-82. However, the combination of GT-055 and GT-1 was not as significant as it was against E. coli
and K. pneumoniae, with only 2 of 11 strains exhibiting a more than 4-fold reduction in MIC (Table 1).
GT-1/GT-055 MICs were equal to or lower than CAZ-AVI or AZT-AVI for all isolates. Specifically,
CAZ-AVI MICs ranged from 4 to >256 µg/mL, and AZT-AVI MICs ranged from 8 to 128 µg/mL, whereas
GT-1/GT-055 MICs ranged from 1 to 128 µg/mL. In addition, GT-055 exhibited no detectable intrinsic
activity against any of the Acinetobacter spp. isolates (MIC > 256 µg/mL).
The porin and siderophore uptake systems and their correlation with GT-1 MICs were also
investigated (Table 2). Only one tonB system is present in E. coli and K. pneumoniae. Whereas, in
Acinetobacter spp., there are three different tonB systems, including tonB, tonB2 and tonB3. However,
the tonB3 system was recognised as the main siderophore uptake system [12], and it was well
conserved among the strains we tested. Only 4/11 strains (YMC2012/07/R3167, YMC2011/02/C582,
YMC2003/05/C86, YMC2013/03/R2081) harboured intact tonB, exbB and exbD genes. Only 2/11 strains
(YMC2013/03/R2081 and YMC2009/02/B2968) had early termination of exbD3, with GT-1 MICs of 16
and 1 µg/mL, respectively. The low GT-1 MIC against the exbD3 mutant strain YMC2009/02/B2968
demonstrated that the deletion of exbD3 has no effect on GT-1 MIC. In addition, 10/11 and 9/11 strains
had a deletion or early termination in bauA and piuA, respectively. The absence or presence of pirA,
fhuA and bfnH did not correlate with high GT-1 MICs against Acinetobacter spp. Moreover, no deletions
of oprD, carD, or 33_36 kDa were observed in the strains exhibiting a high GT-1 MIC (YMC2003/01/R306,
YMC2011/02/C582 and YMC2003/05/C86). This suggested that the high GT-1 MICs against Acinetobacter
spp. were not caused by the loss of porins.
3. Discussion
Resistance among Gram-negative species to existing classes of antimicrobials, including
carbapenems, has limited treatment options for clinicians. In some cases, the only effective option is
colistin, a drug once abandoned due to its serious side effect profile. However, the effectiveness of
colistin has decreased as a result of the rapid spread of mcr-like genes [13]. The next generation of
antibiotics should include new agents that would impede the development of antibiotic resistance
in MDR bacteria. Siderophore-antibiotic conjugants may partially fulfil this requirement. Because
ferric ion is indispensable for bacterial growth and virulence [14,15], any mutations in siderophore
uptake systems during antibiotic treatment could lead to the loss of bacterial virulence, thus ultimately
reducing pathogenicity in host cells. In addition, siderophore uptake may involve more than one
siderophore transporter system [16]; hence, a single mutation in or deletion of one transporter may not
completely prevent siderophore-mediated influx. Consequently, in most cases, multiple mutations
in different bacterial siderophore uptake transporters are required to effectively limit the entry of
a siderophore-antibiotic conjugate [16]. More importantly, loss of function of tonB or tonB3 (in
Acinetobacter spp.), which encodes the primary proton motive force provider for active transport in
Gram-negative bacteria, can completely retard bacterial growth in iron-depleted environments, such
as occurs during an infection [12,17].
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In this study, the novel siderophore cephalosporin, GT-1, exhibited potent activity against many
E. coli, K. pneumoniae and Acinetobacter spp. MDR strains. However, high GT-1 MICs were observed
for some strains. Non-susceptibility to GT-1 exhibited by some K. pneumoniae strains was often
associated with the presence of AmpC β-lactamase DHA-1, for which the GT-1 MICs ranged from 4 to
64 µg/mL, with the exception of strain YMC2011/11/B1440. As we found no sequence differences over
nearly 1000 bp upstream of the blaDHA-1 gene (data not shown), reduced blaDHA-1 expression seems an
unlikely explanation; thus, the reason for the lower GT-1 MIC for this isolate remains to be determined.
As expected, an increase in GT-1 MIC was observed in strain DH5α, which was transformed with
ZpUC19::blaDHA-1, confirming the sensitivity of GT-1 to β-lactamase DHA-1.
In Acinetobacter spp. panel strains, very high GT-1 MICs were observed in strains harbouring
blaPER-1, including YMC2003/01/R306, YMC2011/2/C582, YMC2003/5/C86 and YMC2013/3/R2081.
The significant increase in GT-1 MIC (≥1024-fold, to 32 µg/mL) in E. coli DH5α transformed
with ZpUC19::blaPER-1 supports the hypothesis that blaPER-1 contributes to higher GT-1 MICs in
Acinetobacter spp. strains.
Another important aspect of our study was the systemic evaluation of siderophore uptake systems
and porin loss in E. coli and K. pneumoniae panel strains and the resulting effect on GT-1 MICs. Previous
reports demonstrated that single and double knock-out mutations of cir and fiu in E. coli decrease
inhibition zones of catecholate siderophore-conjugated antibiotics [16]. However, our data suggest that
GT-1 is efficiently transported into E. coli and K. pneumoniae cells with multiple defects in siderophore
transporters. This could be explained by the structure of the GT-1 siderophore, which is a fusion
of hydroxamate and catecholate that can be transported via hydroxamate or catecholate receptors.
In addition, GT-1 did not exhibit a decrease in potency against isolates with single or double deletions
of the porin genes ompC and/or ompF in E. coli or of ompK35 and/or ompK36 in K. pneumoniae. These
results were in accordance with previous findings regarding siderophore-conjugated antibiotics [16]
and suggest that the novel siderophore dihydroxypyridone is a suitable conjugant for the development
of novel antibiotics. We observed similar findings for GT-1 with Acinetobacter spp. strains. In our
analyses, GT-1 MICs were not high in double or triple bauABCDE mutants in strains YMC2012/09/R2209,
YMC2012/01/R79, YMC2011/07/R812 and YMC2003/01/R306. This supports the hypothesis that GT-1
can be taken up via a transport system other than that involved in acinetobactin uptake and underscores
the need for additional studies of GT-1 in this species.
Our study also demonstrated that GT-1 is active against Acinetobacter spp. AmpC-producing
strains (CMY-2-, ADC-22, ADC-25, ADC-30, ADC-31, ADC-77), OXA-carbapenemase-producing
strains (OXA-23, OXA-48, OXA-82, OXA-120, OXA-213, OXA-412, OXA-499), a serine
carbapenemase-producing strain (KPC-2) and a metallo-carbapenemase-producing strain (IMP-1),
with MICs ≤2 µg/mL. The significant potency of GT-1 against Acinetobacter spp. is one of its major
strengths in comparison with CAZ-AVI, as CAZ-AVI is not approved for and exhibits minimal activity
against Acinetobacter spp. Another important advantage is that GT-1 exhibits activity against IMP-1
metallo-β-lactamase–producing isolates, whereas avibactam is inactive against metallo-β-lactamase
producers [18]. In view of the finding that CAZ-AVI resistance has emerged in KPC-producing
K. pneumoniae with the L169P mutation in the Ω loop of KPC-2 and KPC-3 [19,20], GT-1 represents
a potential alternative choice in the antimicrobial arsenal. An additional advantage we found is the
high potency of the synergistic combination of GT-055 and GT-1, in which GT-055 enhanced GT-1
activity in the presence of β-lactamases in CTX-M- (CTX-M-14, CTX-M-15, CTX-M-27, CTX-M-55,
CTX-M-65), SHV- (SHV-12, SHV-83), DHA-1- and SIM-1-producing strains. GT-055 exhibits intrinsic
activity against many Enterobacteriaceae isolates, which likely contributes to its activity in combination
with GT-1 against isolates of E. coli and K. pneumoniae. Recent studies have shown that GT-055 binds
tightly to PBP2 in these species; thus, the synergistic activity of the combination likely reflects both
the ability of GT-055 to inhibit β-lactamases as well as a direct bactericidal effect via PBP2-associated
inhibition of cell wall biosynthesis [11]. The combination of GT-1/GT-055 exhibited better in vitro
activity than AZT-AVI and CAZ-AVI, especially against Acinetobacter spp. panel strains.
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4. Materials and Methods
4.1. Isolates
The clinical isolates examined in this study were obtained from a university-affiliated hospital in
South Korea and collected from 2013 to 2017. For E. coli, approximately 2000 isolates were screened to
select for specific antimicrobial-resistant phenotypes. Acinetobacter spp. and K. pneumoniae isolates
were selected from our previously characterised panel strains [21,22]. Three K. pneumoniae strains
(YMC2016/01/R859, YMC2016/02/N207 and YMC2016/04/N62) exhibiting carbapenem resistance were
also added. Finally, 13 E. coli strains, 14 K. pneumoniae strains and 11 Acinetobacter spp. strains expressing
different β-lactamases (narrow-spectrum and ESBL, KPC- and OXA-carbapenemases, metallo- and
AmpC) were selected. MDR strains were defined as exhibiting resistance to at least three different
antibiotic classes [23].
4.2. Test Compounds
Antibiotic agents included aztreonam (Dong-A Biotech Co., Seoul, Korea), ceftazidime (CJ Health
Care, Seoul, Korea), meropenem (Yuhan Co., Seoul, Korea), imipenem (Choongwae Co., Seoul, Korea)
and colistin (Sigma Aldrich, MO, USA). Avibactam was kindly provided by LegoChem Biosciences.
GT-1 (or LCB10-0200) and GT-055 (or LCB18-055) were manufactured by LegoChem Biosciences.
4.3. Antimicrobial Susceptibility Tests
MICs for bacterial strains were determined using the Mueller–Hinton agar dilution technique,
according to CLSI M07-A10 10th edition and M100 28th edition guidelines (2018) [24,25]. For colistin,
interpretations were based on the European Committee on Antimicrobial Susceptibility Testing
guidelines version 9.0 (2019). Antibiotic agents used as comparators included aztreonam, ceftazidime,
meropenem, imipenem and colistin. The β-lactamase inhibitor avibactam was tested in combination
with aztreonam and ceftazidime. GT-055 was included to assess the synergistic effect with GT-1.
Antibiotic concentrations ranged from 0.12 to 256 µg/mL. GT-055 was tested at 4 µg/mL, similar to
the avibactam concentration recommended by the CLSI guidelines. A previous study reported no
change in GT-1 activity against cells grown on iron-depleted Muller–Hinton medium [26]. Therefore,
the in vitro activity of GT-1 and GT-1/GT-055 under iron-depleted conditions was not assessed in
this study.
4.4. DNA Extraction and Whole-Genome Sequencing
Bacteria were cultured overnight in Luria-Bertani broth at 37 ◦C. One millilitre of the overnight
bacterial culture was used, and genomic DNA was extracted using a Wizard genomic DNA purification
kit (Promega, WI, USA) according to the manufacturer’s instructions. Whole-genome library DNA
was prepared using a Miseq reagent kit v3 and sequenced using Miseq v3.2 × 300-bp paired-end read
cartridges (Illumina, CA, USA).
4.5. Sequence Assembly, Genome Annotation, MLST Determination and Resistome Analysis
Raw reads were assembled using SPAdes v3.11 [27]. Annotations were performed with the Rapid
Annotation using Subsystem Technology pipeline [28]. Resistome data were collected using Resfinder
v1.2 [29] and further verified using NCBI BLAST (http://blast.ncbi.nlm.nih.gov). Genomic analyses
were performed using Geneious pro 8.1.9 (https://www.geneious.com). Bacterial sequence typing was
conducted using the online MLST tool, 1.8 [30].
4.6. Cloning
Following PCR amplification with the primers listed in Table S1, blaDHA-1 with HindIII and EcoRI
restriction site ends and blaPER-1 with BamHI and EcoRI restriction site ends were cloned into ZpUC19.
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The ZpUC19 constructs were then transformed into E. coli DH5α, and GT-1 MICs were determined.
Zeocin (50 µg/mL) was used for colony selection.
4.7. Analysis of Siderophore Uptake System and Porin Loss
Well-characterised siderophore transporters and porins from previous studies were included in
the analysis (Table 4). The GenBank accession numbers of reference sequences are listed in Table S2.
The selected target genes were mapped against the whole genome sequences of the panel strains using
Bowtie alignment [31]. The mapped DNA sequences were translated into protein sequences to identify
mutation-associated alterations affecting protein coding.
Table 4. Siderophore uptake transporters in E. coli, K. pneumonia and A. baumannii.
No. Gene Code Gene Name Membrane Position Reference
1 tonB Ton complex subunit B Inner membrane [32]
2 exbB Biopolymer transport subunit B Inner membrane [32]
3 exbD Biopolymer transport subunit D Inner membrane [32]
4 tonB3 Ton complex subunit B N/D [12]
5 exbB3 Biopolymer transport subunit B3 N/D [12]
6 exbD3 Biopolymer transport subunit D3 N/D [12]
7 fepA Ferric enterobactin outer membrane transporter Outer membrane [33]
8 fepB Ferric enterobactin-binding periplasmic protein Periplasm [34]
9 fepC Ferric enterobactin transport ATP-binding protein Inner membrane [35]
10 fepD Ferric enterobactin transport system permease protein Inner membrane [36]
11 fecA Ferric citrate outer membrane transporter Inner membrane [33]
12 fiu Catecholate siderophore receptor Outer membrane [37]
13 cirA Ferric dihyroxybenzoylserine outer membrane transporter Outer membrane [32]
14 iutA Ferric aerobactin receptor Outer membrane [38]
15 fhuA Ferrichrome outer membrane transporter receptor Outer membrane [33]
16 bauA Ferric acinetobactin receptor Outer membrane [39]
17 bauB Ferric acinetobactin transport system periplasmic binding protein Inner membrane [40]
18 bauC ABC-type enterochelin transport system, permease component Inner membrane [41]
19 bauD Ferric acinetobactin transport system permease Inner membrane [41]
20 bauE ABC-type enterochelin transport system ATPase component N/D [42]
21 pirA Ferric enterobactin receptor Outer membrane [43]
22 piuA Hydroxamate-type ferrisiderophore receptor Outer membrane [43]
23 iroN Salmochelin uptake receptor IroN Outer membrane [44]
24 fyuA Yersiniabactin uptake receptor Outer membrane [45]
25 bfnH Baumannoferrin uptake receptor Outer membrane [46]
N/D: Not determined.
4.8. Accession Numbers
The draft whole-genome sequences of strains YMC2016/06/N138, YMC2016/07/N348,
YMC2017/02/N55, YMC2017/01/N19, YMC2017/07/B11634, YMC2016/02/N176, YMC2016/06/N255,
YMC2017/04/N120, YMC2017/06/P238, YMC2016/01/N95, YMC2016/01/C905, YMC2016/04/R3267,
YMC2016/10/N189, YMC2016/01/R859, YMC2016/02/N207 and YMC2016/04/N62 were deposited
in the NCBI database under the accession numbers SSKC00000000, SSKE00000000, SSJX00000000,
VKOH00000000, SSKB00000000, SSJY00000000, SSKD00000000, VKOI00000000, SSKA00000000,
SSJV00000000, SSJW00000000, SSJZ00000000, SSKF00000000, SSKG00000000, SSKH00000000 and
SSKI00000000, respectively.
5. Conclusions
GT-1 exhibited MICs ≤2 µg/mL against many MDR isolates, including ESBL-, AmpC- and
carbapenemase-producing E. coli and K. pneumoniae and OXA-producing Acinetobacter spp. In addition,
GT-055 enhanced the in vitro activity of GT-1 against GT-1–resistant E. coli, K. pneumoniae and some
isolates of Acinetobacter spp. Finally, DHA-1 and PER-1 increased GT-1 MICs against K. pneumoniae
and Acinetobacter spp. strains, respectively.
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